Dermbits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Summary In the video, Dr. Darrell Rigel explains that the 40-GEP test is a new approach to assess prognosis with squamous cell carcinoma. The test utilizes gene expression profiles (genomics) to provide additional information beyond traditional clinical and histologic factors. By incorporating genomics, the 40-GEP test offers an extra dimension to better evaluate the prognosis of patients with squamous cell carcinoma, potentially leading to more accurate and personalized treatment decisions. Key Points The 40-GEP test is a test that utilizes gene expression profiles to assess prognosis in cases of squamous cell carcinoma. It represents a new approach in contrast to the traditional method of using clinical and histologic factors to determine prognosis. The test offers an advantage by introducing genomics as an additional dimension to improve the accuracy of prognosis assessment. The term "40-GEP" refers to the specific gene expression profile that is analyzed in the test. By incorporating genomic information, the 40-GEP test aims to provide a more comprehensive and precise evaluation of the prognosis for squamous cell carcinoma patients.

Summary In this video, Dr. Michael Cameron discusses the various ways in which alopecia areata can significantly impact the quality of life of patients. He highlights that alopecia areata can have a debilitating effect on a person's emotional well-being due to feelings of embarrassment and anxiety associated with hair loss. Additionally, patients often experience anticipation and stress related to the uncertainty of future hair loss, which can be particularly distressing during significant life events. Furthermore, Dr. Cameron emphasizes that the functional impairment caused by alopecia areata should not be overlooked. For instance, loss of eyebrows can result in sweat getting into the eyes, causing discomfort and inconvenience. Overall, the condition affects individuals in myriad ways, and its impact extends beyond just the physical aspect of hair loss, affecting both emotional and functional aspects of the patients' quality of life. Key Points Alopecia areata can cause a myriad of challenges and impairments to overall well-being and daily life activities. Hair loss from alopecia areata can lead to feelings of embarrassment and anxiety, affecting self-esteem and confidence. The anticipation of future hair loss can cause stress and uncertainty is also negatively impactful. Functional impairment is often overlooked, such as sweat getting into the eyes due to eyebrow loss. The emotional and psychological toll of alopecia areata can be profound and should not be underestimated.

Summary Dr Raj Chovatiya addresses the question of how to identify a patient who would benefit from ruxolitinib cream. He explains that the right patients for this treatment are those with mild to moderate symptoms and a body surface area of involvement between 3% and 20%. These criteria are based on the FDA indication and clinical trial design.In real-world scenarios, patients seeking ruxolitinib cream often have already tried topical corticosteroids or topical calcineurin inhibitors, and a key factor to consider is if patients have not experienced adequate control of their symptoms with these other therapies. The ideal candidate for ruxolitinib cream is someone who desires not only lesional control but also itch control. Overall, identifying patients who would benefit from ruxolitinib cream involves assessing the severity of their condition, the affected body surface area, and the inadequacy of previous treatments in controlling their symptoms. Key Points The key question is: "Who is the right patient for ruxolitinib cream?" The ideal patient profile includes those with mild to moderate symptomsPatients typically have a body surface area of involvement between 3% and 20% Patient candidates have often already tried topical corticosteroids or topical calcineurin inhibitors The target patient is someone who hasn't achieved sufficient control with other therapiesThe desired outcome is not only lesional control, but also itch relief

-